The producer of unique in the world scale device for breast self-examination is starting prospective, multicentre, observational studies, which will confirm the parameters effectiveness of thermographic breast examination with the use of Braster device. INNOMED is the biggest project among all conducted clinical tests. It‘s include 3000 women and will be carry out in 12 clinical centres in Poland.
Thanks to INNOMED project, BRASTER will significantly enlarge database of tomographic screens and will gain possibility for further improvement of an algorithms for data interpretation.
Company is planning also to publish results in international, valued medical journal. Tests results and publication will be a miles stone in creation of consciousness of an international medical community, about using highly effective contact thermography for improving diagnosis of breast cancer.
INNOMED is a research for effectivity of liquid crystal contact thermography for detection of pathological changes in women’s breast gland, compared to standard breast cancer diagnostic methods including mammography and USG. Test will be conducted by The Jagiellonian University - Collegium Medicum (UJCM). For this purpose The Jagielllonian University consortium and Braster company received funding from National Centre for Research and Development (NCBiR) amounted PLN 9.1 MM.
"Clinical studies are an integral part of improving and confirming the diagnostic efficiency of our device. We are currently launching a large-scale study that will cover as many as 3,000 women. The main objective of the study will be to compare the effectiveness of the Braster device for the detection of pathological lesions in the breasts, to the common methods available on the market, and to further improve our method. The results of the study will probably be known by the end of the year." – said Marcin Halicki, President of the Management Board of BRASTER S.A.
In implementing the strategy of international expansion, the Company is planning to pilot the device in one of the selected European markets in the first half of 2017 and in the second half of 2017 enter into other selected EU and US markets with the highest sales potential.